IntroDuctIon
Fungi of the genus Candida grow on mucosal surfaces as part of the normal human flora. When either local or systemic antifungal defense mechanisms are impaired, these organisms can overgrow and cause oropharyngeal candidiasis, leading to significant morbidity in patients with HIV/AIDS 1 , Sjogren's syndrome 2 , diabetes mellitus 3 and head and neck cancers 4 . Although the incidence of oropharyngeal candidiasis has declined in HIV-infected patients treated with highly active antiretroviral therapy 5, 6 , it continues to be a major problem in AIDS patients worldwide 7, 8 . Candida albicans causes at least 80% of cases of oropharyngeal candidiasis in patients with HIV/AIDS 1, 9 . It is also the most common cause of oropharyngeal candidiasis in patients with Sjogren's syndrome, diabetes mellitus and cancer of the head and neck [2] [3] [4] . Azole antifungal drugs are currently the mainstay of therapy 10 . However, resistance to these agents can develop in immunocompromised patients who receive prolonged therapy 1, 9 . Because of the high prevalence of oropharyngeal candidiasis, there is intense interest in developing new approaches to prevent and treat this disease. Although in vitro models mimic some aspects of oropharyngeal candidiasis, experimental animal models are necessary to fully understand the pathogenesis of this disease and to evaluate new treatment and vaccine strategies.
Mouse models of oropharyngeal candidasis
Although rats have been used to study oropharyngeal candidiasis, mice are often preferred because of their relative ease of use and lower cost as well as the greater availability of gene deletion strains. Mouse models of oropharyngeal candidiasis have been used to investigate the immunology of this infection [11] [12] [13] [14] , to identify candidal virulence factors [15] [16] [17] [18] [19] [20] [21] [22] [23] and to assess the efficacy of vaccines and antifungal agents [24] [25] [26] . Multiple experimental models of oropharyngeal candidiasis have been developed (reviewed in ref. 27 ). The key difference among these models is the type of immunosuppression that is used to induce susceptibility to oropharyngeal candidiasis.
Immunocompetent mice are generally not colonized with C. albicans. Furthermore, oral inoculation of immunocompetent mice with most strains of C. albicans, such as the sequenced strain SC5314, typically induces only transient oropharyngeal colonization without the development of disease. However, it has been reported that a strain of C. albicans that was isolated from a patient with oropharyngeal candidiasis could colonize the oropharynx of estrogen-treated mice that did not receive additional immunosuppression 26 . Nevertheless, the oral fungal burden of these mice was relatively low, and the oral isolate did not induce the typical pseudomembranous oropharyngeal candidiasis that is seen in humans.
The simplest approach to induce susceptibility to oropharyngeal candidiasis is to treat mice with corticosteroids 19, 23, 25 . The advantages of this approach are that it can be used with multiple different strains of mice; that immunosuppression is transient, and thus special housing for the mice is not required; and that the histopathology of the lesions mimics those of patients with pseudomembranous oropharyngeal candidiasis (Fig. 1) . In addition, the use of corticosteroids is medically relevant because patients who use inhaled corticosteroids for asthma are at increased risk of developing oropharyngeal candidiasis 28 . Another approach is to use mutant strains of mice with defects in cell-mediated immunity. Mouse strains that are susceptible to oropharyngeal candidiasis is a frequent cause of morbidity in patients with defects in cell-mediated immunity or saliva production. animal models of this infection are important for studying disease pathogenesis and evaluating vaccines and antifungal therapies. Here we describe a simple mouse model of oropharyngeal candidiasis. Mice are rendered susceptible to oral infection by injection with cortisone acetate and then inoculated by placing a swab saturated with Candida albicans sublingually. this process results in a reproducible level of infection, the histopathology of which mimics that of pseudomembranous oropharyngeal candidiasis in humans. By using this model, data are obtained after 5-9 d of work. oropharyngeal candidiasis include those with defects in T cells alone, such as athymic (nu/nu) mice 29 , and those with combined natural killer and T-cell defects, such as beige-athymic (bg/bg-nu/ nu) mice 30 and Tgε26 mice 22 . Another mouse strain that is highly susceptible to oropharyngeal candidiasis is the CD4C/HIV(MutA) transgenic strain, which expresses human immunodeficiency virus type 1 in immune cells 31 . The immune defects in this mouse strain mimic those found in AIDS patients. Finally, it has recently been discovered that the Th17 immune response is crucial for host defense against oropharyngeal candidiasis 11 . Th17-deficient mice that lack either interleukin(IL)-23p19 or the IL-17 receptor are susceptible to oropharyngeal candidiasis without additional immunosuppression 11 . Although the use of these mutant strains obviates the need for administration of corticosteroids, these mice are considerably more expensive than most other mouse strains, frequently have limited availability and may require special housing.
Experimental design
Immunosuppression. In our model, the mice are rendered susceptible to oropharyngeal candidiasis by subcutaneous administration of cortisone acetate, which is administered every other day, starting at day − 1 relative to infection. Oropharyngeal candidiasis persists as long as the cortisone acetate is administered and resolves after it is stopped. The extent of disease can be adjusted by changing the dose of cortisone acetate. We have not observed disseminated infection in mice that have received cortisone acetate at doses of up to 200 mg kg − 1 .
Inoculation. The mice are inoculated by placing a calcium alginate swab saturated with C. albicans blastospores sublingually for 75 min (Fig. 2) . The concentration of organisms in the suspension is not crucial because the course of the infection appears to go through a bottleneck in which only a small number of organisms are present in the oropharynx on day 1 after inoculation. The relatively few organisms present in the oropharynx on day 1 subsequently proliferate to high numbers and induce disease over the ensuing days (Fig. 3) .
To obtain a reproducibly high oral fungal burden, it is necessary to suspend the C. albicans cells in Hanks' balanced salt solution (HBSS) and maintain the suspension at 30 °C while it is being used to saturate the calcium alginate swabs. If the swabs are saturated with organisms that are suspended in a glucose-free medium such as phosphate-buffered saline or if the suspension is kept on ice, then the swabs need to be kept sublingually for at least 90 min to consistently induce infection.
Anesthesia. The most difficult step in the inoculation procedure is keeping the mice adequately sedated while avoiding anesthesiarelated mortality. Mice that are sedated for a prolonged period of time will develop hypothermia if they are kept at room temperature (20-25 °C) . Thus, it is important to maintain the mice on a heating pad until they recover from anesthesia. We use a mixture of ketamine and xylazine to induce sedation and then administer repeated doses of ketamine to maintain sedation for the required time. Even with inbred mouse strains, there is substantial mouse-to-mouse variability in the response to ketamine. Thus, each mouse needs to be monitored individually to determine when an additional dose of ketamine needs to be administered. Signs that a mouse is waking up and needs an additional dose of ketamine include movement of the extremities and blinking of the eyes. We usually administer ketamine at 110 mg kg −1 as the first and second maintenance doses (if needed) and then decrease this dose by 50% after 55-65 min. We do not give any additional ketamine after 65 min, but instead gently restrain any awakening mice for the remaining 10 min.
Disease severity. The extent of disease is determined by two methods. The first is quantitative culture of the tongue, which enables the investigator to assess the oral fungal burden. The second is the histopathological analysis of the infected tongue. We generally stain paraffin-embedded thin sections of the tongue with periodic acid-Schiff, so that both the fungi and the host cells can be analyzed simultaneously. Performing histopathological analysis enables the investigator to verify the quantitative culture results and to assess the extent of fungal filamentation, the depth of tissue penetration, and the number and types of leukocytes that accumulate around the infecting organisms. A third method of estimating disease severity is monitoring individual mice for weight loss. Although this method is noninvasive, we have found that it is associated with substantial experiment-to-experiment variability, making the data difficult to interpret. Anesthetics Combine ketamine and xylazine in sterile PBS so that the final concentration of ketamine is 10 mg ml −1 and xylazine is 1 mg ml −1 . To initiate anesthesia, administer 0.1 ml of this mixture per 10 g of body weight intraperitoneally. Dilute additional ketamine in sterile PBS so that 110 mg kg −1 can be administered in a total volume of 0.2 ml (e.g., 11 mg ml −1 for a 20 g mouse).  crItIcal The anesthetics are not stable for a long period of time, and thus should be prepared on the day of infection. the day before infection 3| Weigh the mice. Use their average weight to calculate the dose of cortisone acetate, which should be administered at a concentration of 225 mg kg − 1 in a total volume of 0.2 ml. The dose that is calculated on the basis of the initial body weight should be administered for all subsequent doses.
4|
Suspend the cortisone acetate in sterile PBS containing 0.05% (vol/vol) Tween 80. The cortisone acetate will not dissolve. To make a fine suspension, either vortex the mixture vigorously or sonicate it for 1 min (i.e., at setting 3 on a Branson sonicator). Store aliquots of the suspension at − 80 °C until needed for days 1 and 3 after infection (days + 1 and + 3).
5|
Inject the animal with 0.2 ml of cortisone acetate subcutaneously in the dorsum of the neck. Use a 1-ml syringe with a 5/8-inch, 25-G needle.  crItIcal step Because the cortisone acetate forms a suspension and does not dissolve, vortex it frequently between injections. In addition, because there is some lot-to-lot variation in the potency of cortisone acetate, use the same lot for a given series of experiments.
6| Place the isothermal pads in a 60 °C water bath overnight. the day of infection 7| Reduce the water bath temperature to 37 °C. Let the isothermal pads remain undisturbed for 1 h at 37 °C before use so as to avoid overheating the mice.
8| Add 1 ml of the YPD overnight culture (from Step 2) to 9 ml of sterile PBS.
9|
Centrifuge at 1,000g for 5 min.
10| Decant the supernatant. Resuspend the pellet in 10 ml of sterile PBS.
11| Repeat Step 9.
12| Decant the supernatant. Resuspend the pellet in 10 ml of sterile HBSS. Vortex vigorously to create a fungal suspension.
13| Dilute an aliquot of the fungal suspension 1:100 in sterile PBS and count the number of organisms with a hemocytometer.
14|
Make up a suspension of 1 × 10 6 organisms ml − 1 in 5 ml of sterile HBSS in a polypropylene tube (17 × 100 mm).
15| Warm the C. albicans suspension to 30 °C in a dry block and place the calcium alginate swabs in the suspension ~5 min before they are used to inoculate the mice.
16|
Remove the isothermal pads from the water bath.  crItIcal step The isothermal pads are crucial for keeping the mice warm and preventing hypothermia while the mice are sedated.
17|
Place two isothermal pads within the stainless steel pan and cover them with a paper towel.
18| By using a 1-ml syringe with a ½-inch, 29-G needle, inject each mouse intraperitoneally with the ketamine/xylazine mixture, administering 0.1 ml per 10 grams of body weight. This dosage will induce 20-30 min of anesthesia.
? trouBlesHootInG
19|
After the mouse is anesthetized, place a saturated calcium alginate swab sublingually for 75 min. Place the mouse in the supine position on the isothermal pad throughout this 75-min period (Fig. 2) .  crItIcal step Monitor each mouse and administer additional doses of ketamine (without xylazine) as necessary to maintain sedation. Although the duration of anesthesia varies with different strains of mice, most will require two additional doses of ketamine to maintain anesthesia for the full 75 min.  crItIcal step Do not administer additional doses of xylazine to maintain anesthesia because it has a longer half-life than ketamine and there is a risk of overdose if multiple doses of xylazine are given.
? trouBlesHootInG one day after infection 20| Inject the animal with 0.2 ml of cortisone acetate subcutaneously in the dorsum of the neck. Use a 1-ml syringe with a 5/8-inch, 25-G needle. Use the same dose that was given on day − 1.
three days after infection 21| Inject the animal with 0.2 ml of cortisone acetate subcutaneously in the dorsum of the neck. Use a 1-ml syringe with a 5/8-inch, 25-G needle. Use the same dose that was given on day − 1.
Five days after infection 22| Set the water bath temperature to 50 °C. Melt the Sabouraud dextrose agar and let the agar sit at 50 °C until needed.
23|
Administer the anesthetic mixture as described in Step 18. Once each mouse is anesthetized, euthanize it by cervical dislocation.  crItIcal step To study the initiation of infection, the mice can be euthanized as early as 1 d after infection.
24| By using the dissecting scissors and forceps, excise the tongue and attached oral tissues and place them on a prelabeled Petri dish. Keep the tissues on ice until the tissue weight is recorded. Note that it is frequently useful to examine the extent of infection by histopathological analysis. To obtain tissue for histopathology, use a scalpel or razor blade to cut the tongue into two pieces with a longitudinal incision in the sagittal plane. Fix one-half of the tongue in zinc-buffered formalin for 4 h at room temperature and process the other half for quantitative culture as described below. Store the fixed tissue in 80% (vol/vol) ethanol before processing for histopathology.
25|
Weigh each tissue sample and record the weights.
26|
Transfer each tissue sample to a 50-ml conical tube containing 5 ml of 0.85% (wt/vol) saline and place the tube on ice.
27|
Homogenize the sample for approximately 8-10 s with the homogenizer with the speed control set at 3. If the tissue is not completely homogenized, cool the tube on ice and then repeat homogenization for an additional 8-10 s. To prevent cross-contamination, rinse the homogenizer probe in a 50-ml centrifuge tube containing 70% (vol/vol) ethanol and then in a tube containing sterile PBS in between experimental groups of mice.
28|
Remove the Sabouraud dextrose agar from the water bath and place the bottle under cold running water. The agar should be cooled to a comfortable temperature when held against the skin.
29|
Prepare serial tenfold dilutions of the homogenate by adding 1 ml of the homogenate to 9 ml of 0.85% (wt/vol) sterile saline.
30|
Plate the undiluted homogenate and each of the serial dilutions in Sabouraud dextrose agar by combining 1 ml of the sample with 12 ml of molten Sabouraud dextrose agar in a Petri dish. Gently swirl the dish to mix.
31|
Incubate the Petri dishes at 35 °C overnight.
32|
The next day, count the colony-forming units.
? trouBlesHootInG steps 18 and 19 As emphasized above, maintaining adequate anesthesia while avoiding anesthesia-related mortality is crucial. Occasionally, a mouse will not be adequately sedated after receiving the ketamine/xylazine mixture. If a mouse remains awake 10 min after the first injection, administer 0.2 ml of the ketamine maintenance solution.
If the initial sedation is successful, but the mice awaken too quickly (within 10 min or less), make sure that the temperature of the procedure room is at least 20 °C. Alternatively, place a heat lamp over the mice to provide additional warming.
If the mice either die during anesthesia or remain sedated for a prolonged time after the 75-min inoculation period, make sure that they are being kept at the correct temperature and are neither becoming hypothermic nor hyperthermic. In addition, try reducing the maintenance dose of ketamine, either by increasing the time interval between the doses or reducing the dose that is administered.
• tIMInG
Step 1, preparation of overnight culture: 10 min (plus incubation time)
Step 2, passage of overnight culture: 10 min (plus incubation time) (Fig. 3) but no mortality. Because of the magnitude of this weight loss, the experiment should be terminated at this time point in order to prevent unnecessary suffering. Reducing the dose of cortisone acetate may decrease the severity of disease and enable the experiment to be carried out for a longer period of time. This mouse model can be used to analyze the virulence of C. albicans mutants 16, 17, 32 , the efficacy of antifungal agents 25 and the host response to mucosal infection 11 . The use of 7 or 8 mice per experimental group usually provides sufficient power to detect a biologically significant tenfold difference in oral fungal burden.
